GlassScriptPhysician profile
Jennifer Jimenez
NPI 1346586112
$36,613.36
in general payments reported to CMS, 2019-2025
22 companies · $2,903 in 2025
The $2,903 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $7,576 · 2022: $1,908 · 2023: $16K · 2024: $7,825 · 2025: $2,903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $9,774 · Travel and Lodging: $443 · Education: $75.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,837.50 |
| Food and Beverage | $9,773.71 |
| Travel and Lodging | $443.23 |
| Education | $75.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $17,648.20 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $5,772.42 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Almatica Pharma LLC | $2,275.35 | 2024-2025 | Loreev Xr |
| Alkermes, INC. | $1,901.87 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,870.72 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,684.92 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,472.85 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $1,131.74 | 2022-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $881.70 | 2021-2025 | Uzedy, Austedo |
| Corium, LLC | $482.89 | 2023-2025 | Azstarys, Azstarys |
| Lundbeck LLC | $363.15 | 2021-2025 | Abilify Maintena |
| Idorsia Pharmaceuticals US INC | $296.08 | 2023-2025 | Quviviq, Quviviq |
| Harmony Biosciences LLC | $222.64 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $127.86 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $113.35 | 2021-2025 | Fanapt |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $105.72 | 2024 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $85.02 | 2025 | |
| Indivior INC. | $78.44 | 2022-2024 | Perseris |
| Noven Therapeutics, LLC | $37.32 | 2021 | |
| Sunovion Pharmaceuticals INC. | $29.69 | 2021 | |
| Avanir Pharmaceuticals, INC. | $17.32 | 2022 | |
| Eisai INC. | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.